

# Abstract Plain Language Summaries at Scientific Congresses



## What are abstract plain language summaries (APLS)?

APLS use simple visuals, plain language and consistent terminology to describe the research presented at scientific congresses, or meetings. Each APLS represents a small piece of the complete body of data available on the drug and disease area today.

*APLS reports represent results of only one study. Researchers must look at the results of many types of studies to understand whether a study drug works, how it works, and whether it is safe to prescribe. The results might be different from the outcome of other studies that researchers have presented in the past. It's important to note that these data are investigational, and the treatments may not be approved in these settings by regulatory agencies.*

Presentations will go live on the dates marked below.

### WHO ARE APLS FOR?

APLS can help research findings be accessible and understandable to anyone seeking this information. Audiences may include but are not limited to patients, caregivers, and healthcare professionals.

### HOW ARE APLS USED?

APLS can help people better understand the research data in presentations at scientific congresses.

### WHAT INFORMATION DO APLS INCLUDE?

APLS summarize the original content of a scientific abstract. They describe the main aims and findings of a research study in an easy-to-understand format by following health literacy best practices.

### WHY DOES PFIZER DEVELOP APLS?

Research findings often use terms that can be too complex for many non-scientists to understand. APLS provide recent research results in a clear way for non-scientists.



## American Society of Hematology (ASH) Annual Meeting & Exposition

New Orleans, Louisiana & Online | December 10-13, 2022

### PFIZER ABSTRACT PLAIN LANGUAGE SUMMARIES AND ACCOMPANYING SCIENTIFIC PRESENTATIONS AT ASH 2022

## Chronic Myeloid Leukemia

Efficacy and safety of bosutinib vs imatinib by Charlson Comorbidity Index in newly diagnosed patients with chronic myeloid leukemia

*Live Saturday, December 10*

[VIEW PLAIN LANGUAGE SUMMARY →](#)

[VIEW PRESENTATION →](#)

Efficacy and safety of bosutinib versus imatinib in US patients with newly diagnosed chronic myeloid leukemia after 5-years follow-up in the BFORE trial

*Live Sunday, December 11*

[VIEW PLAIN LANGUAGE SUMMARY →](#)

[VIEW PRESENTATION →](#)



## Multiple Myeloma

Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma

*Live Saturday, December 10*

[VIEW PLAIN LANGUAGE SUMMARY →](#)

[VIEW PRESENTATION →](#)

Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma naïve to B-cell maturation antigen (BCMA)-directed therapies: Results from cohort A of the MagnetisMM-3 study

*Live Saturday, December 10*

[VIEW PLAIN LANGUAGE SUMMARY →](#)

[VIEW PRESENTATION →](#)

MagnetisMM-4: An open label, phase 1B/2 umbrella study of elranatamab in combination with other anti-cancer treatments for patients with multiple myeloma

*Live Monday, December 12*

[VIEW PLAIN LANGUAGE SUMMARY →](#)

[VIEW PRESENTATION →](#)

Elranatamab in combination with daratumumab for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 MagnetisMM-5 study safety lead-in cohort

*Live Saturday, December 10*

[VIEW PLAIN LANGUAGE SUMMARY →](#)

[VIEW PRESENTATION →](#)

Dose optimization to mitigate the risk of CRS with elranatamab in multiple myeloma

*Live Sunday, December 11*

[VIEW PLAIN LANGUAGE SUMMARY →](#)

[VIEW PRESENTATION →](#)

A systematic meta-analysis of cytokine release syndrome incidence in B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed and/or refractory multiple myeloma

*Live Monday, December 12*

[VIEW PLAIN LANGUAGE SUMMARY →](#)

[VIEW PRESENTATION →](#)

## Acute Lymphoblastic Leukemia

Veno-occlusive disease risk and other outcomes in patients with B-cell precursor acute lymphoblastic leukemia who received inotuzumab ozogamicin and proceeded to hematopoietic stem cell transplantation: A registry-based, observational study

*Live Sunday, December 11*

[VIEW PLAIN LANGUAGE SUMMARY →](#)

[VIEW PRESENTATION →](#)

Health care resource utilization and costs among patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin and blinatumomab during first salvage in relapse/refractory

*Live Sunday, December 11*

[VIEW PLAIN LANGUAGE SUMMARY →](#)

[VIEW PRESENTATION →](#)

## Acute Myeloid Leukemia

Real-world observational study of outcomes for acute myeloid leukemia (AML) in patients treated with glasdegib or venetoclax in US community oncology practices

*Live Saturday, December 10*

[VIEW PLAIN LANGUAGE SUMMARY →](#)

[VIEW PRESENTATION →](#)